Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 555 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: no Condition Clear all
Terminated Phase 4 Interventional Results available

Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present

NCT03655665
View directory record Official record
Conditions
Otitis Media
Interventions
Ofloxacin otic solution
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed No phase listed Observational

A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements

NCT00001077
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Multivitamin and mineral supplements, Peptamen, NuBasics
Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

GABA (Gamma Amino Butyric Acid) Medication for Tobacco

NCT00644137
View directory record Official record
Conditions
Nicotine Dependence
Interventions
pregabalin, cigarettes
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

NCT02518958
View directory record Official record
Conditions
Malignant Solid Tumor, Lymphoma
Interventions
RRx-001, Nivolumab
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 25, 2026, 8:47 PM EDT
Completed No phase listed Observational

Fatigue in Dystonia (a Single Session, Questionnaire-based Study of Fatigue in Dystonia)

NCT00954408
View directory record Official record
Conditions
Dystonia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

NCT00006110
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
1 Year to 120 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 25, 2026, 8:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retinal Fundus Camera Evaluation

NCT02293174
View directory record Official record
Conditions
Normal Healthy Subjects With no Known Ocular Diseases
Interventions
Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 25, 2026, 8:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718
View directory record Official record
Conditions
ALK Fusion-positive Solid or CNS Tumors
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
7
States / cities
Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

NCT00305617
View directory record Official record
Conditions
Lung Cancer
Interventions
antitumor drug screening assay
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks

NCT00690690
View directory record Official record
Conditions
HIV Infections
Interventions
Video (group-delivered video-based intervention), HCT
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 49 Years · Male only
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease

NCT00002324
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Wilmington, Delaware + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

NCT00002243
View directory record Official record
Conditions
HIV Infections
Interventions
Calanolide A
Drug
Lead sponsor
Sarawak MediChem Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 4 Interventional Results available

Paracervical Block Versus No Paracervical Block During IUD Insertion

NCT02904915
View directory record Official record
Conditions
Analgesia, IUD Insertion
Interventions
Lidocaine, No analgesia, Intrauterine device (IUD)
Drug · Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

NCT02030847
View directory record Official record
Conditions
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 8:47 PM EDT
Active, not recruiting Phase 3 Interventional

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557
View directory record Official record
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
111
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709
View directory record Official record
Conditions
Leukemia
Interventions
gemtuzumab ozogamicin, observation, Cytosine arabinoside, Daunomycin
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
255
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 161 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 25, 2026, 8:47 PM EDT
Completed No phase listed Observational Results available

A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

NCT03958071
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pirfenidone, Untreated Cohort
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
13,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Plymouth, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

NCT00489372
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Se-methyl-seleno-L-cysteine, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

NCT00778024
View directory record Official record
Conditions
Healthy
Interventions
fluoxetine HCL 40 mg capsules
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 25, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions
YM598
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 25, 2026, 8:47 PM EDT
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 25, 2026, 8:47 PM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

NCT01394679
View directory record Official record
Conditions
Lung Cancer
Interventions
(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging
Drug
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Not applicable Interventional

APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults

NCT02356835
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
APT001, SHAM
Device
Lead sponsor
Origin Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Montgomery, Alabama • Fresno, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

NCT00445978
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Sapropterin Dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Savannah, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 25, 2026, 8:47 PM EDT